CVS Health Corp

Q2 performance beat expectations across all segments; guidance raised - Adjusted operating income: ~$5.2B (+35% YoY), driven by growth across all three operating segments. - Adjusted EPS: $2.58 (+40% YoY). - Revenue: ~$106B (over +7% YoY). - Full-year 2026 outlook raised: adjusted EPS to $7.90–$8.10 (+$0.60, ~+8% vs prior guidance).

Cash flow and balance sheet strength; capital return limited (no buybacks assumed in guidance) - Cash flow from operations (year-to-date): ~$10.6B. - Full-year 2026 cash flow from operations raised to at least $11.5B (increase of $2B). - Parent cash & unrestricted subsidiaries: ~$2.7B at quarter end. - Leverage: ~3.5x; company expects further improvement. - No share repurchases assumed in the 2026 cash flow/EPS framework (explicitly mentioned); dividends already in motion (returned ~$1.7B through dividends year-to-date).

Key segment drivers and margin commentary (what’s going right) - Health Care Benefits (Aetna): revenue ~$37B (+3% YoY); adjusted operating income ~$2.4B. - Medical Benefit Ratio (MBR): 87.4% (improved vs prior year), with positive items in the quarter including ~$500M (~140 bps) from risk adjustment updates/prior-year development. - Core performance highlighted as exceeding expectations, especially Medicare. - Health Services: revenue ~$52B (+11% YoY); adjusted operating income > $1.7B (+10% YoY). - Pharmacy momentum led by drug mix/brand inflation and specialty strength; modest improvement in health care delivery. - CVS Specialty emphasized as “tech-enabled,” with adherence consistently >90% (vs industry target ~80% cited).